The latest price target for Eli Lilly (NYSE:LLY) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $885.00 expecting LLY to fall to within 12 months (a possible -3.88% downside). 80 analyst firms have reported ratings in the last year.

The latest analyst rating for Eli Lilly (NYSE:LLY) was provided by Cantor Fitzgerald, and Eli Lilly reiterated their overweight rating.

The last upgrade for Eli Lilly and Co happened on August 12, 2024 when Deutsche Bank raised their price target to $1025. Deutsche Bank previously had a hold for Eli Lilly and Co.

The last downgrade for Eli Lilly and Co happened on February 21, 2024 when DZ Bank changed their price target from N/A to $820 for Eli Lilly and Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eli Lilly, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eli Lilly was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Eli Lilly (LLY) rating was a reiterated with a price target of $885.00 to $885.00. The current price Eli Lilly (LLY) is trading at is $920.75, which is out of the analyst’s predicted range.